论文部分内容阅读
Objective Bortezomib plus dexamethasone(BD)and bortezomib,epirubicin plus dexamethasone(PAD)are both front-line regimens of multiple myeloma.This study aimed to assess the efficacy and safety of BD versus PAD regimens in multiple myeloma.Methods All 208patients with newly diagnosed multiple myeloma using either BD or PAD front-line regimens were enrolled be-
Objective Bortezomib plus dexamethasone (BD) and bortezomib, epirubicin plus dexamethasone (PAD) are both front-line regimens of multiple myeloma. This study aims to assess the efficacy and safety of BD versus PAD regimens in multiple myeloma. Methods All 208 patients with newly diagnosed multiple myeloma using either BD or PAD front-line regimens were enrolled be-